98%
921
2 minutes
20
Purpose: To explore the molecular mechanism of G-Rb1 regulating microglia polarization through Wnt/β-catenin signaling pathway to alleviate cerebral ischemia-reperfusion injury in mice.
Methods: C57BL/6J mouse middle cerebral artery occlusion/reperfusion (MCAO/R) model and microglia (BV2) oxygen-glucose deprivation/reoxygenation (ODG/R) model were used. The neuroprotective effect of G-Rb1 and was evaluated by measuring nerve function deficit, cerebral blood perfusion recovery, infarct volume and cell viability. Immunofluorescence, flow cytometry, Western blot and qRT-PCR were used to evaluate the effects of G-Rb1 on the Wnt/β-catenin signaling pathway and microglia phenotypic polarization mediated neuroinflammation and .
Results: Compared with the Sham group, the symptoms of neurological impairment, cerebral blood perfusion, cerebral infarction volume and inflammatory reaction were increased in the IRI group. Compared with the IRI group, G-Rb1 group showed less symptoms of neurological impairment, increased cerebral blood perfusion, decreased cerebral infarction volume, increased proportion of M2-type microglia, increased release of anti-inflammatory factors, reduced inflammatory response, and up-regulated β-catenin expression while down-regulated GSK-3β expression. It was demonstrated that G-Rb1 activates the Wnt/β-catenin signaling pathway after CIRI. Compared with G-Rb1 group, G-Rb1 + XAV939 group had more neurological impairment, increased cerebral infarction volume, increased M1 microglia proportion, and increased neuroinflammation. Meanwhile, β-catenin expression decreased while GSK-3β expression increased. The results of experiments were similar to those of , which demonstrated that G-Rb1 may alter microglial polarization phenotype through Wnt/β-catenin signaling pathway and alleviate neuroinflammatory response after CIRI.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12365930 | PMC |
http://dx.doi.org/10.3389/fnagi.2025.1555067 | DOI Listing |
Helicobacter pylori (H. pylori), a Gram-negative bacterium, has been classified as a Group I carcinogen by the World Health Organization. It represents the most significant modifiable risk factor for gastric cancer (GC), particularly the intestinal subtype.
View Article and Find Full Text PDF